Avrobio (NASDAQ:AVRO) Announces Earnings Results, Beats Estimates By $0.09 EPS

Avrobio (NASDAQ:AVRO) announced its earnings results on Thursday. The company reported ($0.67) EPS for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.09, Bloomberg Earnings reports.

Shares of AVRO traded down $0.80 during midday trading on Friday, hitting $19.24. The company had a trading volume of 282,135 shares, compared to its average volume of 747,012. The company has a 50-day moving average price of $18.24. The firm has a market capitalization of $483.91 million, a price-to-earnings ratio of -5.31 and a beta of 2.70. Avrobio has a 1 year low of $11.85 and a 1 year high of $53.70.

In related news, Director Bruce Booth acquired 810,811 shares of the firm’s stock in a transaction dated Friday, July 19th. The stock was acquired at an average price of $18.50 per share, for a total transaction of $15,000,003.50. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 4.70% of the company’s stock.

A number of equities analysts recently commented on AVRO shares. Mizuho restated a “buy” rating and set a $28.00 target price on shares of Avrobio in a report on Sunday. Cowen restated a “buy” rating on shares of Avrobio in a report on Monday, July 15th. Wedbush restated an “outperform” rating and set a $43.00 target price on shares of Avrobio in a report on Friday. HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of Avrobio in a research note on Friday. Finally, ValuEngine upgraded Avrobio from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Avrobio has a consensus rating of “Buy” and an average target price of $30.63.

Avrobio Company Profile

AVROBIO, Inc, a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease.

Recommended Story: Why is the conference call important?

Earnings History for Avrobio (NASDAQ:AVRO)

Receive News & Ratings for Avrobio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avrobio and related companies with MarketBeat.com's FREE daily email newsletter.